



EUSA PHARMA COMPLETES ESTABLISHMENT OF COMMERCIAL INFRASTRUCTURE WITH APPOINTMENT OF PRESIDENT FOR EUROPE AND INTERNATIONAL REGION

- EUSA presence established in over 80 countries -

- Company positioned for strong growth and profitability in 2010 -

Oxford, UK and Langhorne, PA, USA – 8 March 2010 – EUSA Pharma ('EUSA'), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced the appointment of Iain McGill to the role of President, Europe and International. The appointment marks the completion of the build of both EUSA's executive management team and the company's commercial infrastructure. With EUSA now present in over 80 countries, with teams covering the US and over 20 European territories including the major EU markets, the company anticipates achieving strong sales growth and profitability in 2010.

Mr McGill joins EUSA from Wyeth Pharmaceuticals, where he held the position of Vice President and Global Manager for the company's transplantation business. Previously, he was the Head of Novartis' Transplantation, Immunology and Infectious Diseases Business Unit in Canada, and was a Global Brand Director at Novartis' headquarters in Switzerland. He also held a number of sales and marketing positions of increasing seniority at Novartis and Roche in the UK. Mr McGill holds a BSc in Biochemistry from Royal Holloway College, London University.

"We are delighted to welcome Iain to EUSA at such an exciting time in the company's development," said **Bryan Morton, EUSA Pharma's President and Chief Executive Officer**. "Since founding EUSA four years ago, we have made tremendous progress, raising over \$300 million in investment funding, establishing a portfolio of eight marketed and four pipeline products, and building a strong commercialization platform on both sides of the Atlantic. Iain's leadership skills, and track record of growing specialist pharmaceutical businesses, will prove invaluable as we complete EUSA's transition from a development-stage company to a world leader in its field."

Commenting on his appointment, **Iain McGill, EUSA Pharma's President, Europe and International**, said, "Having seen the team at EUSA build a great company in a very short period of time, I am delighted to join them as we drive the business to the next level. With an infrastructure now in place that can rival even our biggest competitors, EUSA is well positioned to continue its rapid development. I welcome the opportunity to contribute to that progress, as we focus on aggressive organic growth and further product in-licensing and acquisition."

About EUSA Pharma

EUSA Pharma is a rapidly growing transatlantic specialty pharmaceutical company focused on in-licensing, developing and marketing late-stage oncology, pain control and critical care products. The company currently has eight marketed products, including Caphosol[®] for the treatment of oral mucositis, a common and debilitating side-effect of radiation therapy and high dose chemotherapy, Erwinase[®] and Kidrolase[®] for the treatment of acute lymphoblastic leukemia, Collatamp[®] G, a surgical implant impregnated with the antibiotic gentamicin, ProstaScint[®] for imaging the extent and spread of prostate cancer and Quadramet[®] for the treatment of pain in patients whose cancer has spread to the bones. EUSA also has several products in late-stage development.



Founded in 2006, EUSA Pharma is supported by a consortium of leading life science capital investors, comprising Essex Woodlands, 3i, Goldman Sachs, Advent Venture Partners, SV Life Sciences, TVM Capital, NeoMed and NovaQuest. Since its foundation, the company has raised over \$300 million, and completed several significant transactions, including the acquisitions of Cytogen Corporation, Talisker Pharma Limited, the French biopharmaceutical company OPi SA and the European antibiotic and pain control business of Innocoll Pharmaceuticals Inc. Key to its rapid growth strategy is the company's established commercial infrastructure in the US, pan-European presence covering over 20 countries and wider distribution network in a further 60 territories. EUSA Pharma plans to continue its aggressive program of acquisitions and in-licensing, in line with its ambitious target to become the leading specialty company in its areas of therapeutic and geographic focus.

Contacts

Bryan Morton
Chief Executive
EUSA Pharma
Tel: +44 (0)1865 784255

Rob Budge
RJB Communications
Tel: +44 (0)1865 760969
Mobile: +44 (0)7710 741241